CA2029940A1 - Utilisation de nouvelles microspheres injectables biodegradables, procede de preparation de ces nouvelles microspheres et suspension injectables les renfermant - Google Patents
Utilisation de nouvelles microspheres injectables biodegradables, procede de preparation de ces nouvelles microspheres et suspension injectables les renfermantInfo
- Publication number
- CA2029940A1 CA2029940A1 CA002029940A CA2029940A CA2029940A1 CA 2029940 A1 CA2029940 A1 CA 2029940A1 CA 002029940 A CA002029940 A CA 002029940A CA 2029940 A CA2029940 A CA 2029940A CA 2029940 A1 CA2029940 A1 CA 2029940A1
- Authority
- CA
- Canada
- Prior art keywords
- radical
- carbon atoms
- microspheres
- carbon
- represent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000004005 microsphere Substances 0.000 title claims abstract description 59
- 238000000034 method Methods 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title claims abstract description 6
- 229940102213 injectable suspension Drugs 0.000 title 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims abstract description 56
- 229920001577 copolymer Polymers 0.000 claims abstract description 38
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 32
- 230000001833 anti-estrogenic effect Effects 0.000 claims abstract description 22
- 239000000328 estrogen antagonist Substances 0.000 claims abstract description 22
- 150000003431 steroids Chemical class 0.000 claims abstract description 21
- 239000000725 suspension Substances 0.000 claims abstract description 10
- -1 radical hydrocarbon Chemical group 0.000 claims description 70
- 125000004432 carbon atom Chemical group C* 0.000 claims description 51
- 150000003254 radicals Chemical class 0.000 claims description 48
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 34
- 229910052799 carbon Inorganic materials 0.000 claims description 31
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 27
- 125000004429 atom Chemical group 0.000 claims description 27
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 25
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 claims description 24
- 229940046836 anti-estrogen Drugs 0.000 claims description 21
- 239000002253 acid Substances 0.000 claims description 14
- 229920006395 saturated elastomer Polymers 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- DBLOJPKZEOYNBN-SQNIBIBYSA-N (8s,13s,14s)-13-methyl-2,6,7,8,11,12,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 DBLOJPKZEOYNBN-SQNIBIBYSA-N 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical group ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- 125000003342 alkenyl group Chemical group 0.000 claims description 7
- 125000000304 alkynyl group Chemical group 0.000 claims description 7
- 125000005842 heteroatom Chemical group 0.000 claims description 7
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical group [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 claims description 7
- 239000012074 organic phase Substances 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 150000007513 acids Chemical class 0.000 claims description 6
- 239000008346 aqueous phase Substances 0.000 claims description 6
- 150000001721 carbon Chemical group 0.000 claims description 6
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical group [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 claims description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 5
- 239000003995 emulsifying agent Substances 0.000 claims description 5
- 150000002576 ketones Chemical group 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 230000000962 progestomimetic effect Effects 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 238000001704 evaporation Methods 0.000 claims description 4
- 230000008020 evaporation Effects 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 239000012071 phase Substances 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 125000006017 1-propenyl group Chemical group 0.000 claims description 3
- 239000004215 Carbon black (E152) Substances 0.000 claims description 3
- 125000001931 aliphatic group Chemical group 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 125000000732 arylene group Chemical group 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical group C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 claims description 3
- XEHVFKKSDRMODV-UHFFFAOYSA-N ethynyl Chemical compound C#[C] XEHVFKKSDRMODV-UHFFFAOYSA-N 0.000 claims description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims description 3
- 229930195733 hydrocarbon Natural products 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 claims description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 3
- RDKRLZMGGDOEPU-UHFFFAOYSA-N n-methyl-8-phenyloctanamide Chemical compound CNC(=O)CCCCCCCC1=CC=CC=C1 RDKRLZMGGDOEPU-UHFFFAOYSA-N 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 150000000795 D-homosteroids Chemical group 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 238000009940 knitting Methods 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 229940011871 estrogen Drugs 0.000 claims 1
- 239000000262 estrogen Substances 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940102223 injectable solution Drugs 0.000 description 2
- 238000011866 long-term treatment Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000007127 saponification reaction Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 101100370282 Caenorhabditis elegans tra-4 gene Proteins 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 108010052300 RA X peptide Proteins 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- ORTFAQDWJHRMNX-UHFFFAOYSA-M oxidooxomethyl Chemical compound [O-][C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-M 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical class S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR898914976A FR2654337B1 (fr) | 1989-11-15 | 1989-11-15 | Nouvelles microspheres injectables biodegradables procede de preparation et suspensions injectables les renfermant. |
| FR8914976 | 1989-11-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2029940A1 true CA2029940A1 (fr) | 1991-05-16 |
Family
ID=9387417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002029940A Abandoned CA2029940A1 (fr) | 1989-11-15 | 1990-11-14 | Utilisation de nouvelles microspheres injectables biodegradables, procede de preparation de ces nouvelles microspheres et suspension injectables les renfermant |
Country Status (13)
| Country | Link |
|---|---|
| JP (1) | JPH03294229A (de) |
| AT (1) | AT400298B (de) |
| BE (1) | BE1005511A4 (de) |
| CA (1) | CA2029940A1 (de) |
| CH (1) | CH681691A5 (de) |
| DE (1) | DE4036425A1 (de) |
| DK (1) | DK270990A (de) |
| FR (1) | FR2654337B1 (de) |
| GB (1) | GB2239798B (de) |
| IT (1) | IT1242010B (de) |
| LU (1) | LU87836A1 (de) |
| NL (1) | NL9002492A (de) |
| SE (1) | SE9003570L (de) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010082149A1 (en) | 2009-01-16 | 2010-07-22 | Exelgyn | Sprm pharmaceutical compositions methods of treatment using them |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA924811B (en) * | 1991-06-28 | 1993-12-29 | Endorecherche Inc | Controlled release systems and low dose androgens |
| HU222501B1 (hu) * | 1991-06-28 | 2003-07-28 | Endorecherche Inc. | MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására |
| ES2105525T3 (es) * | 1993-06-24 | 1997-10-16 | Lilly Co Eli | 2-fenil-3-aroilbenzotiofenos antiestrogenicos como agentes hipoglicemicos. |
| US5910492A (en) * | 1995-06-05 | 1999-06-08 | Takeda Chemical Industries, Ltd. | Osteogenic promoting pharmaceutical composition |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4293539A (en) * | 1979-09-12 | 1981-10-06 | Eli Lilly And Company | Controlled release formulations and method of treatment |
| US4389330A (en) * | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
| ZA8231B (en) * | 1981-01-09 | 1982-11-24 | Roussel Uclaf | New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained |
| FR2528434B1 (fr) * | 1982-06-11 | 1985-07-19 | Roussel Uclaf | Nouveaux 19-nor steroides substitues en 11b et eventuellement en 2, leur procede de preparation et leur application comme medicament |
| US4530840A (en) * | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
| FR2537980B1 (fr) * | 1982-12-17 | 1986-12-19 | Sandoz Sa | Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation |
| ES8502612A1 (es) * | 1983-06-15 | 1985-02-01 | Schering Ag | Procedimiento para la preparacion de 13a-alquilgonanos |
| GB8327256D0 (en) * | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
| JPS60100516A (ja) * | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
| DE3347126A1 (de) * | 1983-12-22 | 1985-07-11 | Schering AG, 1000 Berlin und 4709 Bergkamen | 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate |
| FR2566779B2 (fr) * | 1984-06-29 | 1987-03-06 | Roussel Uclaf | Nouveaux derives steroides substitues en 11b, leur procede de preparation et leur application comme medicaments |
| CA1256638A (en) * | 1984-07-06 | 1989-06-27 | Motoaki Tanaka | Polymer and its production |
| FR2573657B1 (fr) * | 1984-11-29 | 1989-05-12 | Roussel Uclaf | Produit comprenant une substance antiprogestomimetique et une substance uterotonique |
| DE3533175A1 (de) * | 1985-09-13 | 1987-03-19 | Schering Ag | Antigestagene zur verschiebung der endometrialen reifung |
| FR2596395B1 (fr) * | 1986-03-26 | 1989-05-26 | Roussel Uclaf | Nouveaux steroides comportant un cycle spirannique en position 17, leur procede de preparation, leur application comme medicaments et les compositions les renfermant |
| US4758435A (en) * | 1986-08-11 | 1988-07-19 | American Cyanamid Company | Estradiol implant composition and method for preparation |
| DE3633244A1 (de) * | 1986-09-26 | 1988-03-31 | Schering Ag | Antigestagene zur hemmung der uterinen prostaglandinsynthese |
| EP0310542B1 (de) * | 1987-10-01 | 1994-06-08 | Schering Aktiengesellschaft | Antigestagen- und antiöstrogenwirksame Verbindungen zur Behandlung hormonabhängiger Tumoren |
| DE3733478A1 (de) * | 1987-10-01 | 1989-04-13 | Schering Ag | Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore |
| DE3744054A1 (de) * | 1987-12-21 | 1989-06-29 | Schering Ag | Verwendung von antigestagenen zur herstellung von arzneimitteln |
| JP2785023B2 (ja) * | 1987-12-30 | 1998-08-13 | ルセル―ユクラフ | １７α位置を置換された１７β―ＯＨ―１９―ノルステロイドの新誘導体、その製造方法、その薬剤としての使用及びそれを含有する製薬組成物 |
| JP2670680B2 (ja) * | 1988-02-24 | 1997-10-29 | 株式会社ビーエムジー | 生理活性物質含有ポリ乳酸系微小球およびその製造法 |
-
1989
- 1989-11-15 FR FR898914976A patent/FR2654337B1/fr not_active Expired - Fee Related
-
1990
- 1990-11-08 LU LU87836A patent/LU87836A1/fr unknown
- 1990-11-09 BE BE9001062A patent/BE1005511A4/fr not_active IP Right Cessation
- 1990-11-09 SE SE9003570A patent/SE9003570L/ not_active Application Discontinuation
- 1990-11-13 IT IT48470A patent/IT1242010B/it active IP Right Grant
- 1990-11-13 DK DK270990A patent/DK270990A/da not_active Application Discontinuation
- 1990-11-14 CA CA002029940A patent/CA2029940A1/fr not_active Abandoned
- 1990-11-14 CH CH3611/90A patent/CH681691A5/fr not_active IP Right Cessation
- 1990-11-14 JP JP2306374A patent/JPH03294229A/ja active Pending
- 1990-11-15 AT AT0231390A patent/AT400298B/de not_active IP Right Cessation
- 1990-11-15 NL NL9002492A patent/NL9002492A/nl not_active Application Discontinuation
- 1990-11-15 DE DE4036425A patent/DE4036425A1/de not_active Withdrawn
- 1990-11-15 GB GB9024862A patent/GB2239798B/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010082149A1 (en) | 2009-01-16 | 2010-07-22 | Exelgyn | Sprm pharmaceutical compositions methods of treatment using them |
| EP2210585A1 (de) | 2009-01-16 | 2010-07-28 | Exelgyn | Pharmazeutische SPRM-Zusammensetzungen, Behandlungsverfahren unter Anwendung dieser |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2654337B1 (fr) | 1994-08-05 |
| DK270990D0 (da) | 1990-11-13 |
| NL9002492A (nl) | 1991-06-03 |
| IT1242010B (it) | 1994-02-02 |
| LU87836A1 (fr) | 1991-05-07 |
| IT9048470A1 (it) | 1992-05-13 |
| ATA231390A (de) | 1995-04-15 |
| AT400298B (de) | 1995-11-27 |
| IT9048470A0 (it) | 1990-11-13 |
| SE9003570D0 (sv) | 1990-11-09 |
| CH681691A5 (de) | 1993-05-14 |
| GB9024862D0 (en) | 1991-01-02 |
| FR2654337A1 (fr) | 1991-05-17 |
| JPH03294229A (ja) | 1991-12-25 |
| GB2239798B (en) | 1993-10-27 |
| BE1005511A4 (fr) | 1993-08-31 |
| GB2239798A (en) | 1991-07-17 |
| SE9003570L (sv) | 1991-05-16 |
| DK270990A (da) | 1991-05-16 |
| DE4036425A1 (de) | 1991-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LU88001A1 (fr) | Nouveaux esters pregna-1,4-diene-3,20-dione-16-17-acetal-21,procede pour leur preparation,et methodes pour le traitement des conditions inflammatoires | |
| WO1991015193A1 (fr) | Microspheres, leur procede de preparation et leur utilisation | |
| FR2537980A1 (fr) | Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation | |
| LU84439A1 (fr) | Nouveaux derives du 3-amino pregn-5-ene,leurs sels,leur preparation,leur application a titre de medicaments et les compositions les renfermant | |
| EP0280618A1 (de) | In Stellung 7 substituierte 19-Norsteroide, ihre Herstellung, ihre Anwendung als Arzneimittel und die Zusammensetzungen, die sie enthalten | |
| WO2015177469A1 (fr) | Composés chimiques et leur utilisation pour l'amélioration de la qualité musculaire | |
| CA2029940A1 (fr) | Utilisation de nouvelles microspheres injectables biodegradables, procede de preparation de ces nouvelles microspheres et suspension injectables les renfermant | |
| CA2576393C (fr) | Nouveaux derives du 3,5-seco-4-nor-cholestane et leurs utilisations | |
| EP0080941A1 (de) | Pyrimidoquinoxaline, ihre Herstellung, ihre Verwendung als Arzneimittel und diese enthaltende Zubereitungen | |
| EP0308284A1 (de) | 1,2,5,6-Tetrahydropyridinoxim-Derivate, Verfahren zu deren Herstellung, deren Verwendung als Arzneimittel und diese enthaltende Zusammensetzungen | |
| EP0091328B1 (de) | Trans-4-aminobenz(c,d)indol-5-ol Verbindungen, deren Salze, deren Herstellung, deren Verwendung als Arzneimittel und diese enthaltende Zusammensetzungen | |
| EP0101383B1 (de) | 14-Aminosteroidderivate, ihre therapeutische Anwendung und Verfahren zu ihrer Herstellung | |
| CA1065851A (fr) | Procede pour l'obtention du compose 17-alpha-ethinyl (5 alpha) 2-androstene 17 beta-ol a l'etat pur et applications therapeutiques du compose obtenu par ce procede | |
| FR2494697A1 (fr) | Nouveaux derives steroides 3-amines, leurs sels, procede et intermediaires de preparation, application a titre de medicaments et compositions les renfermant | |
| BE898430A (fr) | Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation. | |
| CH672887A5 (de) | ||
| CN1777586A (zh) | 稳定的无定形樟脑磺酸氨氯地平、其制备工艺以及其口服给药的组合物 | |
| CH620688A5 (en) | Process for the preparation of new lactones derived from cyclopentanol | |
| CH674845A5 (de) | ||
| WO2008056059A2 (fr) | Derives de 4-azasteroles, leurs procedes de synthese et leur utilisation a titre de medicament | |
| EP1230252A1 (de) | Beta-d-thioxylos-derivate, verfahren zur herstellung und verwendung als arzneimittel | |
| FR2444M (de) | ||
| CA1202631A (fr) | Derives de la quinidine, procede de preparation et application en therapeutique | |
| CA1175415A (fr) | Procede de preparation de nouveaux derives steroides 3-amino substitue | |
| WO1992001706A1 (fr) | Nouveaux derives de la 6-methyl 19-nor progesterone, substitue en 3 et leur procede d'obtention |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |